Transatlantique Private Wealth LLC Acquires 105 Shares of Johnson & Johnson (NYSE:JNJ)

Transatlantique Private Wealth LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,302 shares of the company’s stock after acquiring an additional 105 shares during the quarter. Transatlantique Private Wealth LLC’s holdings in Johnson & Johnson were worth $758,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in JNJ. TPG Advisors LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $246,000. Summit Trail Advisors LLC grew its holdings in Johnson & Johnson by 30.7% in the second quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company’s stock worth $6,712,000 after purchasing an additional 10,789 shares during the last quarter. Kiely Wealth Advisory Group Inc. lifted its holdings in shares of Johnson & Johnson by 5.7% during the 2nd quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company’s stock valued at $296,000 after purchasing an additional 99 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Johnson & Johnson by 31.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock worth $238,951,000 after purchasing an additional 394,518 shares in the last quarter. Finally, Sei Investments Co. increased its position in Johnson & Johnson by 10.7% during the 2nd quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock valued at $164,672,000 after buying an additional 109,205 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. The Goldman Sachs Group lowered their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. TD Cowen dropped their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Friday. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $164.11 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a 50 day moving average price of $161.30 and a 200-day moving average price of $154.20. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $394.96 billion, a price-to-earnings ratio of 10.23, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. The company’s revenue was up 4.3% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.